The global medical environment is being redefined by AI technology, fundamentally reorganizing healthcare management. In particular, the adoption of AI in lung cancer screening is accelerating, which is transforming the U.S. medical ecosystem. At the heart of this innovation is Coreline Soft’s FDA-approved solution, 'AVIEW LCS Plus.' This solution goes beyond simple disease detection, leading to an innovative shift in efficiently diagnosing various thoracic diseases. AVIEW LCS Plus is an AI-based simultaneous diagnosis solution for thoracic diseases, supporting medical professionals' diagnostic and treatment decisions through automated image analysis, thus bringing innovation to the medical process. By providing a more precise health analysis platform to clinical settings and patients, it further enhances the accuracy and efficiency of diagnoses, indicating the increasing importance of AI in the future of medicine. In this interview, Korea IT Times highlights the advanced technologies and vision of Coreline Soft as well as insights from James Lee, Head of Coreline North America, regarding the trends in U.S. medical AI amid the growing importance of AI-based automated image interpretation, incidental findings, and opportunistic screening.
James Lee, Head of Coreline North America
Recent Trends in U.S. Medical AI: Incidental Findings and AI-Based Screening
Q: How is AI impacting lung cancer screenings in the U.S., and what are the latest trends?
A: AI technology is advancing towards a more comprehensive interpretation of radiological examination data. With the introduction of AI, the efficiency of detecting incidental findings has increased. For instance, one CT scan can identify not only lung nodules but also COPD, coronary artery calcification, osteoporosis, and other conditions. These technological innovations help radiology specialists and clinicians optimize patient management, reduce unnecessary imaging, and improve early intervention strategies. In this trend, the U.S. Preventive Services Task Force (USPSTF) and the American College of Radiology (ACR) are evaluating the efficiency and clinical impact of AI-based lung cancer screening and discussing clearer definitions of AI-assisted reading roles.
Competitive Edge Making AVIEW LCS Plus a Game-Changer
Q: What differentiates AVIEW LCS Plus from other AI solutions?
A: A key differentiator of AVIEW LCS Plus is its multi-disease detection capability. Through a single scan, it can simultaneously detect lung cancer, COPD, coronary artery calcification, and osteoporosis. Furthermore, it is designed to be easily integrated into existing PACS and radiology workflows, making it a highlighted case of quality management using AI in lung cancer screening.
AVIEW LCS Plus has demonstrated its reliability in ongoing lung cancer screening projects across Germany, Italy, and five other European countries. It has also shown remarkable results in Korea’s K-lukas. Currently, it is being used in collaboration with over 80 institutions as part of the national cancer screening program and was presented as a best practice combining efficient medical data management with AI-based precise interpretation at IACCS 2024.
Lastly, UI and UX play a crucial role. AVIEW's interface was originally strong and received FDA approval last February. While most AI solutions provide results in a post-analysis manner, Coreline Soft offers an 'editor viewer' enabling observation, modification, and manipulation in 3D graphics. This aspect addresses the AI 'black box' problem and is useful for research. The viewer allows 3D examination of AI-interpreted results or images, facilitating research on solutions across various domains, such as the brain, abdomen, and muscles. This comprehensive and systematic product and platform benefit both patients and healthcare providers.
Research and Validation: Clinical Impact of AI
Q: Are there studies supporting the effectiveness of AVIEW LCS Plus?
A: Clinical validation is crucial. Recent findings have shown that AVIEW LCS Plus significantly supports enhancing diagnostic process efficiency as an AI solution suitable for first-reader use.
According to a recent study by the Institute for Diagnostic Accuracy (IDNA), AVIEW LCS Plus enhances diagnostic accuracy while significantly reducing the workload of radiologists. Verified results published on December 28th in the European Journal of Cancer demonstrated the potential for AI as a primary reading tool. In this study, AVIEW LCS was found to be much less likely than human radiologists to erroneously identify nodules larger than 100 cubic millimeters, strengthening the basis for utilizing AI technology as a primary tool in lung cancer screening interpretation.
Clinical Comments: Temple Health’s Customer Feedback
Q: How do customers respond to AVIEW LCS Plus?
A: At the Temple Lung Center, a leading institution in pulmonary health, significant achievements have been made by fully integrating AVIEW LCS Plus into the Healthy Chest Initiative, leveraging AI for improved patient screening. Temple's nurse navigators are using these results to support systematic patient-tailored follow-up and care. Dr. Gerard Criner, director of Temple Lung Center, noted that AI-based analysis aids in streamlining the patient management process and improving both the speed and accuracy of diagnoses. He particularly emphasized that AI helps reduce the time required for manual interpretation, enhances classification efficiency, and is valuable in the early detection of high-risk patients.
The Future of AVIEW LCS Plus
Q: What are the future plans for AVIEW LCS Plus?
A: AVIEW LCS Plus is evolving beyond a mere lung cancer screening tool into a comprehensive thoracic health analysis platform. The AVIEW product line not only reports AI results but also uses its own viewer to apply 3D visualization techniques, enabling medical staff to confirm AI-analyzed results more clearly and accurately through visual inspection.
This technology allows for a more intuitive understanding of complex data, thereby increasing the reliability of healthcare professionals and maximizing the efficiency of diagnostic and treatment decisions. Furthermore, should medical staff disagree with AI results, the solution provides features that allow them to easily adjust the findings and assist them in delivering more tailored care to patients. Initiatives like the Temple Healthy Chest Initiative and the BLVR program are setting new standards for diagnosis and treatment by integrating Coreline Soft’s technologies. Thus, Coreline Soft is positioning itself not just as a provider of innovative AI technologies but as a solution partner that adds real value for both healthcare professionals and patients.
AI is no longer just a simple assistant; it has become a core component of medical imaging. Coreline Soft is committed to advancing AI and supporting the future of precision medicine. Currently, the company is expanding its capabilities from comprehensive analysis of relevant diseases in thoracic CT to areas like brain, abdominal, and spinal CT, broadening the range of applicable diseases to include hemorrhagic stroke, cerebrovascular examinations, quantitative analysis of fatty liver, body fat assessments, and spinal canal stenosis screenings.
